2021
- What data supported the removal of the pregnancy contraindication from statin labeling?
- What literature is available on selective serotonin reuptake inhibitor use for post-stroke recovery?
- What evidence is available regarding the efficacy of COVID-19 vaccine booster shots in adults?
- What are the 2021 guideline updates on the management of Clostridioides difficile infection (CDI) in adults?
- Are there data available to support use of fixed-dose cisatracurium for acute respiratory distress syndrome (ARDS)?
- What are the implications of the COVID-19 pandemic on respiratory syncytial virus (RSV) infection prophylaxis with palivizumab?
- What data support a thrice-weekly regimen of ertapenem therapy in patients with end-stage renal disease on intermittent hemodialysis?
- What literature is available describing the occurrence of bradycardia with remdesivir?
- What is the clinical evidence supporting, and controversy surrounding, the use of aducanumab (Aduhelm TM) for Alzheimer disease?
- What evidence is available for use of the newest mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease?
- Are there any data to support administration of a second course of intravenous immunoglobulin in patients with Guillain-Barré syndrome unresponsive to a first course?
- 2021 Update: What are considerations for determining whether a drug may be administered via a midline catheter?
- What are current recommendations for filtering parenteral nutrition (PN) admixtures?
- What evidence is available regarding thrombosis and thrombocytopenia associated with adenoviral vector-based COVID-19 vaccines?
- What information is available on the management of potential drug interactions with the COVID-19 vaccine?
- What recommendations are available regarding the timing of administration of the COVID-19 vaccine with regard to immunosuppressant medications?
- Update: What is the evidence for use of high-dose vitamin C in critically ill patients with sepsis?
- What evidence supports the addition of metronidazole to the standard regimen of ceftriaxone and doxycycline for the treatment of pelvic inflammatory disease?
- What data are available to support extended-release bupivacaine/meloxicam for post surgical analgesia?
- Why has bacitracin for injection been withdrawn, and are alternative irrigation solutions recommended to prevent pocket infection during implantation of cardiovascular implantable electronic devices?
- In patients with severe COVID-19, are there data to support the use of dexamethasone or methylprednisolone doses greater than dexamethasone 6 mg daily or equivalent?
- What drugs are likely to interfere with urine drug screens?
- What evidence supports new disease-modifying drug therapies in sickle cell disease?
- Update: What is the optimal dosing of 4-factor prothrombin complex concentrate in patients with warfarin-associated bleeding?
- What is the evidence on the use of high-dose nitroglycerin for SCAPE?
- What evidence is available regarding the off-label use of spinal mepivacaine versus bupivacaine for total hip and total knee arthroplasty?
- What evidence is available for intranasal esketamine as a treatment for acute depression/suicidal ideation in the emergency department?
- What technology is used in vaccines against coronavirus disease 2019?
- What should I, as a pharmacist, know about long-COVID?
- What is the place in therapy for monoclonal antibodies in outpatients with COVID-19?
- What are current recommendations for treatment of drug extravasation?
- What evidence supports the use of Clorpactin (sodium oxychlorosene) for the treatment of urinary tract infections?
- Update: What is the evidence for the use of albumin for treatment of intradialytic hypotension?
- Update: What do pharmacists need to know about convalescent plasma for COVID-19?
- Should appetite stimulants be used in pediatric patients with cancer?
- What vaccines should be administered to adult patients who have asplenia or hyposplenia?
- What is the risk of QT prolongation with droperidol?